Caris Life Sciences Publishes npj Precision Oncology Study Showing AI-Guided Therapy Selection is Predictive of Longer Survival in Patients with Pancreatic Cancer
Caris Life Sciences published a study in npj Precision Oncology validating its Caris AI Insights tool for predicting first-line treatment benefit in pancreatic cancer. In the testing cohort, patients predicted to benefit from FOLFIRINOX achieved a median overall survival of 16.0 months compared to 9.9 months for those treated with gemcitabine plus nab-paclitaxel.
Key figures
- Median survival gem nab p months
- 9.9
- Median survival folfirinox months
- 16
AI analysis
The rest of the AI analysis, red flags and sentiment are part of Signal8 Pro.
AI-generated analysis of a public disclosure. Not investment advice; verify against the original document.